MedPath

Survival Rates and Quality of Life According to Follow-up Period After Gastrectomy for Gastric Cancer (STOFOLUP)

Not Applicable
Recruiting
Conditions
Gastric Cancer
Recurrence
Quality of Life
Interventions
Diagnostic Test: Computed tomography, Chest X-ray, and blood test
Registration Number
NCT04740346
Lead Sponsor
National Cancer Center, Korea
Brief Summary

This study is a multi-center, prospective, randomized controlled study. The aim of this study is to compare survival rates and to observe quality of life and nutritional status according to follow-up period in patients who underwent radical gastrectomy for stage 2 or 3 gastric cancer.

Detailed Description

The hypothesis of this study is that the survival rates would be different between the 3 months and 6 months follow-up groups. The investigators expected survival differences of 6% and the anticipated 3-year overall survival is 83% in the 6 months follow-up group based on the previous 3 phase clinical trial. On the basis of this hypothesis, the sample size was calculated as 886 patients.

Patients who were diagnosed as stage 2 or 3 gastric cancer after gastrectomy will be assigned to 3 months or 6 months follow-up group. The planned examinations including blood test, X-ray , CT, endoscopy, and nutritional markers will be performed according to the protocol and each patients will be followed up for 3 years after enrollment.

The primary endpoint is 3 year overall survival and secondary endpoints are other survivals such as 3-year disease-free survival and gastric cancer specific survival, quality of life, and nutritional parameters.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
886
Inclusion Criteria
  • Patients aged 19 years or more
  • Patients who are diagnosed with pathological stage II or III gastric adenocarcinoma according to the AJCC 8th edition
  • Patients who can understand all information about the trial and decide for themselves whether to participate in this study
Exclusion Criteria
  • Vulnerable patients such as pregnant and intellectual disability
  • Patients who cannot undergo CT owing to poor kidney function or severe adverse effects
  • Patients who are already in another study and cannot follow the schedule for this trial
  • Patients who are diagnosed with a cancer other than gastric cancer within five years before the gastrectomy
  • Patients being treated for a cancer other than gastric cancer

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
3 months follow-upComputed tomography, Chest X-ray, and blood testPatients will be follow-up every 3 months after gastrectomy.
6 months follow-upComputed tomography, Chest X-ray, and blood testPatients will be follow-up every 6 months after gastrectomy.
Primary Outcome Measures
NameTimeMethod
3-year overall survival3 years after surgery

Death from any cause is defined as an event.

Secondary Outcome Measures
NameTimeMethod
Incidence of iron deficiency anemia3 years after surgery

Incidence of iron deficiency anemia for the 3 year follow-up after gastrectomy

3-year recurrence-free survival rate3 years after surgery

Death from any cause and gastric cancer recurrence are an event.

3-year gastric cancer specific survival rate3 years after surgery

Death from gastric cancer is the only event.

3-year post-recurrence survival rate3 years after surgery

from recurrence detection date to last follow-up date (or death)

Summary score of KOQUSS-40 questionnaire3 years after surgery

KOQUSS-40 consists of 8 domains with 40 questions for quality of life and post-gastrectomy symptoms. We will calculate the KOQUSS-40 summary score of each group and compare them between the two groups. The summary score is defined as the mean of eight symptom domains (Indigestion, dysphagia, reflux, dumping syndrome, bowel habit change, constipation, psychological factors, and worry about cancer). The minimum and maximum values are 0 and 100, and higher scores mean a better quality of life.

Summary score of EORTC QLQ C303 years after surgery

EORTC QLQ C30 consists of 15 domains with 30 questions for quality of life of cancer patients. The 15 domains consist of five functional scales (physical, role, cognitive, emotional, and social functioning), a global QOL scale, three symptom scales (fatigue, nausea and vomiting, and pain), and six single items (appetite loss, diarrhea, dyspnea, constipation, insomnia, financial impact).

We will calculate the EORTC QLQ C30 summary score of each group and compare them between the two groups. The summary score is defined as the mean of 13 domains (excluding global QOL scale and financial impact). The minimum and maximum values are 0 and 100, and higher scores mean a better quality of life.

Summary score of EORTC QLQ STO223 years after surgery

EORTC QLQ STO22 consists of 9 domains with 22 questions for stomach cancer patients' symptoms. The 9 domains consist of five symptom scales (dysphagia, pain, reflux symptom, eating restriction, anxiety), four single items (having a dry mouth, taste, body image, and hair loss).

We will calculate the EORTC QLQ STO22 summary score of each group and compare them between the two groups. The summary score is defined as the mean of 9 domains. The minimum and maximum values are 0 and 100, and higher scores mean a better quality of life.

Difference of body weight (kg)3 years after surgery

Difference of body weight between preoperative and postoperative 3 year values

Incidence of vitamin B12 deficiency3 years after surgery

Incidence of vitamin B12 deficiency for the 3 year follow-up after gastrectomy

Trial Locations

Locations (16)

Kangbuk Samsung Hospital

šŸ‡°šŸ‡·

Seoul, Korea, Republic of

Seoul National University Hospital

šŸ‡°šŸ‡·

Seoul, Korea, Republic of

Chonnam National University Hwasun Hospital

šŸ‡°šŸ‡·

Hwasun, Korea, Republic of

Asan Medical Center

šŸ‡°šŸ‡·

Seoul, Korea, Republic of

Seoul St. Mary's Hospital

šŸ‡°šŸ‡·

Seoul, Korea, Republic of

Yonsei Univeristy College of Medicine

šŸ‡°šŸ‡·

Seoul, Korea, Republic of

Ajou University School of Medicine

šŸ‡°šŸ‡·

Suwon, Korea, Republic of

CHA Bundang Medical Center

šŸ‡°šŸ‡·

Seongnam, Korea, Republic of

Keimyung University Dongsan Hospital

šŸ‡°šŸ‡·

Daegu, Korea, Republic of

Kyungpook National University Chilgok Hospital

šŸ‡°šŸ‡·

Daegu, Korea, Republic of

Samsung Medical Center

šŸ‡°šŸ‡·

Seoul, Korea, Republic of

National Cancer Center, Korea

šŸ‡°šŸ‡·

Goyang, Gyeonggi-do, Korea, Republic of

Dongnam Institute of Radiological and Medical Sciences

šŸ‡°šŸ‡·

Busan, Korea, Republic of

Gyeongsang National University Changwon Hospital

šŸ‡°šŸ‡·

Changwon, Korea, Republic of

Kosin University Gospel Hospital

šŸ‡°šŸ‡·

Busan, Korea, Republic of

Gyeongsang National University Hospital

šŸ‡°šŸ‡·

Jinju, Korea, Republic of

Ā© Copyright 2025. All Rights Reserved by MedPath